“Understanding the epidemiology and complex burden of progressive kidney disease”
— Dr. med. Christian Schmidt-Lauber
Kidney diseases pose a significant challenge to global health, explained by the high prevalence and the debilitating consequences on various other organs associated with chronic kidney disease (CKD). However, understanding is evolving that acute kidney injury (AKI), which has conventionally been seen as a transient occurrence, also significantly contributes to long-standing adverse effects on multiple organs, progression of CKD, and the increased long-term mortality. As such, AKI aligns with traditional risk factors for progressive kidney disease, such as hypertension and diabetes. These somatic risk factors are accompanied by demographic and socioeconomic determinants as well as an increasing set of medical treatments influencing kidney diseases or their risk factors.
Our group aims to better understand this complex web of disease modifiers within the trajectory of kidney diseases, their consequences, as well as hypertension, as one of the major somatic risk factors. Additionally, we try to elucidate the underlying role of inflammation, which is emerging as a major pathophysiological component within the kidney disease trajectory. Our work includes a broad set of epidemiological strategies and methods and is performed on large population-based studies (Hamburg City Health Study), AKI and CKD cohort studies (Hamburg and European Renal Omics Bank), as well as overarching nationwide German and Danish registries. This undertaking is conducted with the support of national and international collaborating partners.
Junior Group Leader
III. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE)
Martinistr. 52
20246 Hamburg, Germany
since 2024
|
Junior group leader supported by the BMBF iSTAR Advanced Clinician Scientist program |
since 2023 |
Spokesperson of the Research Alliance of the Hamburg City Health Study |
since 2022 |
Attending physician, Department of Medicine, University Medical Center Hamburg- Eppendorf, Germany |
2007- 2014
|
Medical School, University Münster, Germany |
2014 |
Practical training University of California Medical School, Department of Medicine, San Diego, USA |
2021 - 2020
|
Board Certification in Nephrology and Internal Medicine |
2021
|
Certification as expert in hypertension (DHL®) |
2019
|
Board Certification in Emergency Medicine |
2013
|
Dissertation as Doctor of Medicine, University Münster, Germany (summa cum laude) |
Clinical postgraduate education:
2019 - 2021
|
Residency in Nephrology and Internal Medicine, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Germany |
2016 |
Visiting Clinician, Department of Nephrology, Yale University, New Haven,USA |
2015 - 2019
|
Residency in Nephrology and Internal Medicine, Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürmberg, Germany |
Scientific education:
2012 - 2015
|
Research Fellow, Division of Experimental Nephrology, Department of Internal Medicine D, and Institute of Musculoskeletal Medicine, University Hospital Münster, Germany |
2011 - 2012
|
Research Fellow, Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, USA |
2024 - 2020
|
Dr.-Günther-Sawitzki-Award of the German Society for Hypertension (DHL®) |
2023
|
Best Poster Award, German Society of Transplantation (DTG) |
2022
|
“Teacher of the year” Award, University Medical Center Hamburg-Eppendorf, Germany |
2015
|
Award for the best Medical Thesis, University of Münster, Germany |
1. | Acute kidney injury predicts mortality in very elderly critically-ill patients. |
2. | Kidney outcome after mild to moderate COVID-19. |
3. | Molecular consequences of SARS-CoV-2 liver tropism. |
4. | Increased rejection rates in kidney transplantations during the COVID-19 pandemic. |
5. | Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. |
Martinistraße 52
Campus Research N27
20246 Hamburg Germany